Overview

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis

Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the dose response based on the efficacy, safety and tolerability of bimekizumab in subjects with active psoriatic arthritis.
Phase:
Phase 2
Details
Lead Sponsor:
UCB Biopharma S.P.R.L.